Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report.

@article{Sato2017BevacizumabPC,
  title={Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report.},
  author={Emi Sato and Kentaro Nakayama and Kohei Nakamura and Tomoka Ishibashi and Hiroshi Katagiri and Masako Ishikawa and Satoru Kyo},
  journal={Molecular and clinical oncology},
  year={2017},
  volume={7 3},
  pages={391-394}
}
The prognosis of patients with recurrent/persistent endometrial cancer, particularly type II cancer, remains poor, and effective treatment has not yet been established. We herein present the case of a patient with recurrent type II endometrial cancer who received bevacizumab + chemotherapy continued beyond progression, after previously receiving bevacizumab + chemotherapy. This patient experienced recurrence after first- and second-line adjuvant chemotherapy followed by modified radical… CONTINUE READING